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Abstract
Background: Recent work, using both cell culture model systems and tumour derived cell lines,
suggests that the differential recruitment into polysomes of mRNA populations may be sufficient
to initiate and maintain tumour formation. Consequently, a major effort is underway to use high
density microarray profiles to establish molecular fingerprints for cells exposed to defined drug
regimes. The aim of these pharmacogenomic approaches is to provide new information on how
drugs can impact on the translational read-out within a defined cellular background.
Methods:  We describe an approach that permits the analysis of de-novo mRNA-ribosome
association in-vivo during short drug exposures. It combines hypertonic shock, polysome
fractionation and high-throughput analysis to provide a molecular phenotype of translationally
responsive transcripts. Compared to previous translational profiling studies, the procedure offers
increased specificity due to the elimination of the drugs secondary effects (e.g. on the
transcriptional read-out). For this pilot "proof-of-principle" assay we selected the drug rapamycin
because of its extensively studied impact on translation initiation.
Results: High throughput analysis on both the light and heavy polysomal fractions has identified
mRNAs whose re-recruitment onto free ribosomes responded to short exposure to the drug
rapamycin. The results of the microarray have been confirmed using real-time RT-PCR. The
selective down-regulation of TOP transcripts is also consistent with previous translational profiling
studies using this drug.
Conclusion: The technical advance outlined in this manuscript offers the possibility of new insights
into mRNA features that impact on translation initiation and provides a molecular fingerprint for
transcript-ribosome association in any cell type and in the presence of a range of drugs of interest.
Such molecular phenotypes defined pre-clinically may ultimately impact on the evaluation of a
particular drug in a living cell.
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Background
Dissecting the specific effect of a drug on a defined biolog-
ical process is often complicated by the plethora of sec-
ondary effects that arise during extended exposure. This is
highlighted by the anti-cancer drug rapamycin whose
principle, although not exclusive, target is the rate limiting
initiation step of protein translation [1]. Techniques
designed to analyse the effect of the drug on mRNA-ribos-
ome association are hampered by the long exposure times
required to observe changes in the polysomal mRNA pop-
ulations. Translation initiation is frequently regulated via
the  eukaryotic  initiation  factor 4E (eIF4E). It can be
sequestered into an inactive complex by a family of 4E-
binding proteins (4E-BP1/2/3). The affinity of these pro-
teins for eIF4E is modulated by phosphorylation via the
mTORC1 (mammalian target of rapamycin complex 1)
kinase [2]. Rapamycin arrests many cells in G1 [3], and is
a potent immunosuppressant [4]. It exerts its action by
binding and inactivating the mTORC1 [5]. Previous stud-
ies have shown that extended exposure to rapamycin also
alters transcription. Among the mRNAs regulated, a
number impact directly on translation (e.g. eIF2α) [6].
These changes were minor after short drug exposure times
(< 60 mins), but increased markedly after 2 hrs. Transla-
tional profiling studies (which examine the mRNAs asso-
ciated with ribosomes) have also been reported [7-10].
One study, performed on the Jurkat T cell clone E6-1,
revealed that after an extended exposure to rapamycin
(minimum 4 hrs) almost all transcripts analysed were
inhibited, and 136 of those (representing ~5% of the
total) were strongly inhibited (at least 10 fold). This latter
group included a number of mRNAs whose products
impact directly on translation (e.g. eIF5A, eIF4A1, eEF1,
eEFTu) [8]. This would predict that lengthy exposure to
the drug will influence translation by modifying the levels
of initiation and elongation factors. We therefore sought
to develop a technique that would permit a specific anal-
ysis on how the drug alters transcript recruitment onto
free ribosomes under conditions that eliminated the sec-
ondary effects associated with extended exposure. The
approach has been coupled to a high-throughput micro-
array screen to examine how rapamycin exposure impacts
on the re-seeding of the polysomal transcript populations.
Results from the array have also been validated by quanti-
tative RT-PCR.
Methods
Cell culture
MRC-5 cells (Coriell Cell Repository) were cultured in
Minimal Essential Medium (Gibco) supplemented with 1
mM sodium pyruvate (Sigma), 0.1 mM non-essential
amino acids, 10% foetal calf serum (Brunschwig), 1%
penicillin/streptomycin, in a humidified atmosphere con-
taining 5% CO2. For polysome analysis, cells in the grow-
ing phase (60% confluence) were hypertonically shocked
by shifting to medium containing 300 mM NaCl for 50
min. They were then placed in normal isotonic medium
for 30 min. When rapamycin was used, 100 nM rapamy-
cin (LC laboratories) or 0.01% DMSO (the negative con-
trol) was added during the hypertonic shock, 20 min
before the transfer back to isotonic conditions. Rapamy-
cin and DMSO were kept on the cells throughout the 30
mins recovery period (total time of exposure to rapamycin
was 50 mins). These conditions were based upon previ-
ously published work [11], although we have independ-
ently confirmed that they can be used on a range of cell
lines including 293T [12], HeLa S3 and SK-NA5 (data not
shown).
Polysome gradient/RNA extraction
After treatment, cells were scraped into the culture
medium and pelleted for 4 min at 100 g. The pellets, con-
sisting of 5 × 106 cells, were lysed for 15 min on ice in 400
μL of 100 mM KCl, 50 mM Tris-Cl pH 7.4, 1.5 mM MgCl2,
1 mM DTT, 1 mg/mL heparin, 1.5 % NP40, 100 μM
cycloheximide, 1% aprotinin, 1 mM AEBSF and 100 U/
mL of RNasin. Nuclei were pelleted by centrifugation in a
microfuge, 10 min at 12000 rpm. The supernatant was
loaded onto a 20–60% sucrose gradient (in 100 mM KCL,
5 mM MgCl2, 20 mM HEPES pH 7.4 and 2 mM DTT).
Extracts were fractionated for 3 h 30 min at 35,000 rpm at
4°C in a Beckman SW41 rotor, and the gradients were
recovered in 3 fractions [monosome, light polysome (2 to
5 ribosomes) and heavy polysome (> 5 ribosomes)] using
a Brandel gradient fractionator equipped with an ISCO
UA-6 flow cell set to 254 nm. RNA was isolated from the
light and heavy polysome fractions by adding an equal
volume of TriZol (Invitrogen). Samples were mixed and
incubate for 15 min. on ice, then 0.3 volumes of chloro-
form was added. After centrifugation, the upper phase was
collected and the RNA precipitated with 0.7 volumes of
isopropanol. The pellet of RNA was re-suspended in
water. Prior to microarray analysis the pooled RNA frac-
tions were further purified using the Qiagen RNeasy kit.
The total yield of RNA in each pooled fraction was ~2 μg.
RNA quality was checked on an Agilent 2100 bioanalyser.
Microarray
Total RNA (100 ng from each fraction) was first amplified
using the two step amplification protocol of Affymetrix.
cRNA (17.5 μg) was then used to probe the Gene Chip
U133 Plus 2.0 with 54,675 probe sets, covering more than
47,000 transcripts. Three biological replicates were
hybridised for each condition (light and heavy polysomes
+/- rapamycin). Data were analysed using the GCOS nor-
malisation of Affymetrix. After normalisation, we filtered
out probe sets that were assayed "absent" in all the 12
arrays. For this, the expression levels in each control exper-
iment (DMSO) were arbitrarily fixed to one, and the fold
change of the corresponding probe in the treated samplesBMC Medical Genomics 2008, 1:33 http://www.biomedcentral.com/1755-8794/1/33
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was normalised to this. The variation was then tested
using the Mann and Witney U statistical test. Using this
approach 24,105 of the probe sets (44%) were flagged as
absent. The data was further analysed using two
approaches. Firstly, probe set intensity values below 100
were removed prior to GCOS normalisation, and fold
changes ≥ 1.5 relative to the DMSO control were scored
(the smallest score in the three independent experiments
had to show at least a 20% change relative to the DMSO
control i.e. a 1.2 fold increase or a 0.8 fold decrease). In a
second approach, commencing with the entire data set,
points were only scored if the mean of the fold difference
was ≥ 2.5 (once again the smallest score in the three inde-
pendent experiments had to show at least a 20% change
relative to the DMSO control). The data from both screens
were plotted onto biological networks using the GO
onthology (Affymetrix) and Ingenuity Pathway Analysis
Software packages http://www.Ingenuity.com.
The microarray data are available at ArrayExpress (Acces-
sion N° E-TABM-205).
Real-Time PCR
One μg of total RNA from a fourth independent experi-
ment was reverse transcribed using random hexamers
(Gibco). A 1/10 dilution of the cDNA was used to perform
the PCR with the SYBR Green Reagent (Roche).
Primers used were:
QKI  AGCATCACAGTCAGAGGTCAGC, GCAGTGGCAT-
ATTAAACCAAAGC;
RBM7  GTTGGAAATTCAAGCCCTACCT, AATCCTGATT-
GATCCAGAGGTG;
ORMDL1  GTCTGGCAGAAACAACGTCTC, CAATGT-
GGTTGCTGTTCTGG;
FAS  GATGGCGAATGAGGTTCAG, CAATCCCATATCTC-
CCATTAAC;
RBM17  GTCATCTCCGGTGATCCTTAAA, CAACCAGA-
GAGGCACACAGAT;
PAPPA  GCATCAGTTTCTCTAGCTGCAA, TAT-
CAAACAAGCACTCCCTGTC;
Actin  CTGACGGCCAGGTCATCACCATTG, GCCG-
GACTCGTCATACTCCTGCTTG;
L27  GTGACAGCTGCCATGGGCAAG, TCAAACTTGAC-
CTTGGCCTCCCG,
Cyclin D1 AAGCAGGACTTTGAGGCA AG, CCTCTGAG-
GTCCCTACTTTCAA.
Primer sets were designed to amplify regions within the 3'
UTR of each transcript since this generally corresponded
to the site of the probe sets used on the Affymetrix chip.
The specificity of each primer set was confirmed by stand-
ard RT-PCR on total cell RNA, followed by analysis of the
DNA products by agarose gel electrophoresis (data not
shown).
Western blot analysis
Cells were lysed in CSH buffer (50 mM Tris-Cl pH 7.5,
250 mM NaCl, 1 mM EDTA, 0.1% Triton X-100) and the
nuclei were pelleted by centrifugation at 12,000 rpm for 5
mins. Twenty μgs of protein was resolved on a 15% poly-
acrylamide-SDS gel and electrotransfered to a PVDF mem-
brane. Antibodies used in this study were the anti-4EBP1
(Cell Signalling), the anti-phosho4EBPI (Thr37/46) (Cell
Signalling), the anti-p70 S6 kinase (Cell Signalling), the
anti-phospho-p70 S6 kinase (Thr389) (Cell Signalling)
and mouse anti-actin (Chemicon). Blots were developed
using the Super Signal Substrate (Thermo Scientific).
Results
Rapamycin delays mRNA recruitment onto polysomes
To directly examine the effect of rapamycin on mRNA
recruitment we decided to exploit a novel approach, an
approach that analyses the ability of cellular mRNAs to
compete for free ribosomes in-vivo. Hypertonic shock
provokes a rapid inhibition of protein synthesis, disaggre-
gation of polysomes (Figure 1A), dephosphorylation of
eIF4E, 4E-BP1, S6 and an increased association of eIF4E
and 4E-BP1 [11,13]. Upon restoration of isotonic condi-
tions the polysomal fraction is rapidly reconstituted (Fig-
ure 1B and [11]). Using this methodology it was possible
to examine what effect rapamycin had on the recruitment
of mRNA populations onto free ribosomes following very
short drug exposure times. It was in substance an in-vivo
competition assay performed under two defined physio-
logical conditions. Drug treatment appeared to delay
recruitment as evidenced by the reduction in the heavy
polysome peak (≥ 6 ribosomes: compare Figure 1B and
1C), and this effect was correlated with a modification of
the downstream signalling targets of mTOR, including 4E-
BP1 and S6 kinase. (Figure 1D, compare the second and
third lanes). This confirmed that despite the relatively
short time of exposure to rapamycin, the recruitment
assay monitored transcript:ribosome re-association under
two conditions in which eIF4E availability was altered.
A profiling screen identifies changes in the light and heavy 
polysomal mRNA populations
Equal amounts of RNA isolated from the light (2 to 5
ribosomes) and heavy (> 5 ribosomes) polysomal frac-BMC Medical Genomics 2008, 1:33 http://www.biomedcentral.com/1755-8794/1/33
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tions were used to probe the Affymetrix Gene Chip U133
Plus 2. Triplicate independent gradients under each exper-
imental condition were examined. After data analysis, two
subpopulations of transcripts were clearly discriminated:
those dominant in the light polysomal fraction and those
dominant in the heavy polysomal fraction, an important
criterion since it validated the initial experimental
approach (Figure 2A). Despite the fact that the polysomal
peaks were smaller in the presence of rapamycin, consist-
ent with a global repression, the two sub-populations
were essentially conserved (i.e. no major movement of
mRNA populations between the two fractions as a conse-
quence of the treatment was evident). To analyse the data
we used two approaches. Firstly, we filtered out all tran-
scripts giving low probe set intensity values on the chip
using the default settings of the Agilent analysis software
package (values < 100). We then scored for mRNAs whose
polysomal occupancy was altered by greater than ×1.5
fold (listed in Additional File 1). This produced 437 tran-
scripts within which was found the majority of the
repressed TOP mRNAs (see below). Curiously, within this
group of transcripts almost equal proportions were up
and down-regulated (46% and 54%, respectively) (Figure
2B).
As a second approach to analyse the data we applied a
×2.5 fold change cut-off point to the entire data set. The
rationale for this alternative analysis is based upon the
fact that many of the genes that are regulated at the level
of translation are frequently transcribed at low levels. This
includes proto-oncogenes and other factors that regulate
cell growth [14]. The majority of these transcripts are
found within the lower intensity range and we therefore
tested if meaningful information could be extracted from
Ribosomal re-recruitment in the presence of rapamycin Figure 1
Ribosomal re-recruitment in the presence of rapamycin. (A). High salt provokes a rapid disaggregation of polysomes. 
(B). Upon restoration of isotonic conditions the polysomal fraction is reconstituted (C). Pre-treatment with rapamycin delays 
the re-recruitment of ribosomes. The position of the ribonucleoprotein (RNP), the monosomal (Mono) and polysomal (Poly) 
fractions are indicated. (D) Western blot analysis of phospho-4EBP-1, 4EBP-1, phospho-S6K, S6K, and actin was performed on 
extracts isolated under the different conditions depicted in panels (A); (B) and (C).
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Microarray analysis Figure 2
Microarray analysis. (A). Hierarchical clustering of relative expression. Each column represents the different conditions. On 
the right the vertical bar indicates probe set intensity values (indicated as Expression) in arbitrary units. The zero value indi-
cates absence, with blue indicating a low level and red a high level of expression (the maximum value being fixed as 5). The ver-
tical brackets on the right indicate that transcripts have been grouped into those over-represented in the light polysomes 
(lower) or in the heavy polysomes (upper). (B). After removal of probe set intensity values < 100, and the application of a ×1.5 
fold cut-off, the regulated genes were classified into four groups. The values indicate the number of transcripts in each group. 
(C). In a second approach, a ×2.5 fold cut-off was applied. (D) and (E). Functional classification using Gene Ontology of the 
genes either up-regulated or down-regulated (as depicted in panel b and in Additional File 1, and panel c and in Additional File 
2, respectively). The unknown fraction represents genes not annotated in the Gene Ontology database.BMC Medical Genomics 2008, 1:33 http://www.biomedcentral.com/1755-8794/1/33
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this region by applying a more stringent selection. We
observed that 1160 mRNAs (3.8%) showed increased or
decreased polysomal distribution in the presence of
rapamycin, suggesting that in this small fraction of tran-
scripts the affinity for the cap binding complex was
changed (Figure 2C and Additional File 2). Over 2/3 of
the mRNAs responding to the drug were down-regulated,
whereas 1/3 showed increased polysomal occupancy rele-
vant to the non-treated control. Only a few transcripts
were regulated in both the heavy and the light polysomes
(55 mRNAs) (Figure 2C). These results are not unlike
those reported in a translational profiling study per-
formed on the two tumoural cell lines, LAPC-4 (prostrate
cancer) and U87 (glioblastoma). Applying the 2.5 fold
cut-off point, ca. 6% of the 3,000 transcripts screened
showed altered polysomal occupancy, and amongst these,
60% were down-regulated and 40% up-regulated [7].
Those mRNAs showing significant redistributions (both
increased and decreased: as listed in Additional Files 1 and
2) were then plotted onto cellular networks using the GO
onthology (Affymetrix) software package. Results revealed
that transcripts up- or down-regulated affected more or
less the same biological processes (Figure 2D and 2E).
However, using the Ingenuity pathway analysis a number
of features were immediately evident in the rapamycin
treated cells: (a) A group of mRNAs involved in the
inflammatory response were regulated, consistent with
the immunosuppressive activity of rapamycin. Interest-
ingly, we also observed down-regulation of several tran-
scripts linked to phagocytosis. It has recently been
reported that rapamycin down-regulates phagocytosis in a
murine macrophage cell line (Table 1) [15]. (b) We
observed a number of mRNAs involved in cell growth and
proliferation. Among them, a number of anti-apoptotic
mRNAs were up-regulated (e.g. relA and mdm2), whereas
pro-apoptotic ones were down-regulated (e.g. fas, faslg
and faf1) (Table 1). This is consistent with the observation
that rapamycin did not induce apoptosis in MRC-5 cells
even after extended exposure (unpublished observations),
and corroborated recent studies showing the anti-apop-
totic properties of rapamycin [16,17].
Rapamycin is known to have a marked effect on the
expression of a subset of transcripts referred to as terminal
oligopyrimidine (TOP) mRNAs [18]. This includes ribos-
omal protein mRNAs (estimated to be ~15% of the total
cellular mRNA) and translation elongation factors. In pre-
vious translational profiling studies, a number of TOP
mRNAs were clearly repressed. We also observed repres-
sion of ribosomal transcripts, although the effects were
less extensive than in the earlier reports. This may reflect
both the shorter drug exposure times and the experimen-
tal approach that was employed (i.e. mRNA re-recruit-
ment onto free ribosomes). With the cut-off threshold at
×2.5 fold we observed down regulation of rpl14 and rpl21
in the light polysomes and rplp0 in the heavy polysomes
(ribosomal protein large). However, if the threshold was
reduced to ×1.5 fold the number of hits significantly
increased. Most significantly, ribosomal transcripts were
only ever observed down-regulated (Table 2 and Addi-
tional File 1).
Independent confirmation of the array results by RT-PCR
With the aim of validating the microarray we performed
real-time RT-PCR on selected transcripts across the spec-
trum of probe set intensities (Figure 3A). We were partic-
ularly interested in those transcripts that gave low probe
set values. For the RT-PCR, RNA was extracted from a
fourth independent experiment. Nine mRNAs were ini-
tially selected (Transcripts up-regulated = qki, rbm7,
ormdl1. Transcripts down-regulated = fas, rbm17, pappa,
Transcripts not regulated = β-actin, L27, cyclin D1: see
Additional Files 1 and 2). Transcripts from the lower val-
ues of the data set (see Additional File 2 and Figure 3A)
were selected because of the large fold difference between
the rapamycin and DMSO control (> 2.5 fold). The
results, with the exception of those obtained with the
pappa transcript, largely confirmed the micro-array data
(Figure 3B). This was particularly encouraging for tran-
scripts such as those coding for QKI and FAS, indicating
that application of the ×2.5 fold cut-off approach permit-
ted the extraction of useful hits even in the lower end of
the probe intensity set (Figure 3A). Note that the absence
of a light RT-PCR value for RBM17 simply reflected its low
levels in this fraction (Ct > 35 cycles). The microarray
study also indicated that this transcript was regulated only
within the heavy polysomal fraction, a result confirmed
by the RT-PCR. In addition, these studies also demon-
strated that no significant changes in total mRNA levels
had occurred within the selected transcripts as a conse-
quence of drug exposure (Figure 3B).
Discussion
In this technical report, we have outlined a novel
approach to translational profiling that follows the
impact of a drug on the de-novo re-association of mRNAs
and ribosomes in living cells in culture. An intracellular
pool of free ribosomes was generated by a short hyper-
tonic shock. Although this undoubtedly induced a stress
response, previous work has demonstrated that the trans-
lation initiation machinery recovers very rapidly after the
cells are transferred back to isotonic conditions as moni-
tored by the reconstitution of the polysomal fraction
[11,13]. The rapidity at which the polysomes are reformed
has permitted us to examine the effect of a drug on this
process using a short time window of exposure. This has
the effect of limiting undesirable secondary effects that
arise upon extended exposure, an effect highlighted by the
drug selected for this study, namely rapamycin (see Intro-BMC Medical Genomics 2008, 1:33 http://www.biomedcentral.com/1755-8794/1/33
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Table 1: List of transcripts regulated by rapamycin (Ingenuity classification)
Inflammation
Upregulated Downregulated
apobec3f lst1 adra1a epha4 il1rn ptpn22 tlr7
blnk mdm2 adra2c f9 irf2 ptprc zeb1
cald1 oas1 alpp fas itgb3 ptprz1
cmklr1 parvg bcl11a faslg klf2 rbl2
ctla4 pdgfc bcl2l1 fcgr2a lama3 rbm15
cxcr4 rag2 cast folr1 lilra2 rbpj
cyp3a4 rela cd28 fyb mll rel
fyn sat1 cd36 gal mpo satb1
hla-g tcf12 clec1b gap43 pcgf2 siglec8
ifih1 tfap4 cul4a gnrh1 pla2g6 smpd1
ifna2 thbs1 cxcl11 gnrhr plcg1 spn
il16 tlr7 cyp3a4 hal-dqb1 prdm16 syk
il28b unc119 ddl1 hck pscdbp thra
itga4 vtcn1 dok2 ifne1 ptgs2 thrb
Cell growth and proliferation
Upregulated Downregulated
adam12 mdm2 adra1a dok2 gnrh1 olig2 rffl
blnk pappa bcl2l1 f12 hck p53aip1 sec14l2
cdc2l5 rag2 ccl27 fas hmga2 pcgf2 syk
ctla4 rela cd28 faslg irf2 pdgfa tfr2
cxcr4 s100b cdca7 fbxo2 itgb3 piwil1 tgif1
erbb3 ss18 clca2 fcer2 klf2 pla2g6 thra
fyn tcf12 cltc fgf18 lzts1 ptgs2 thrb
hla-g thbs1 csh2 folr1 mdm4 ptk2 tnfsf15
igf1r unc119 cyp2c9 foxo1 mll ptpn22 zfn10
il28b vtcn1 dcc gal nab2 ptpra
itga4 ddx17 gap43 nos1 ptprc
lst1 dll1 glmn nov rbl2
Cell death
Upregulated Downregulated
blnk itga2 abcd2 dll1 hmga2 p53aip1 rbm17
cdk6 mdm2 acvr1b eraf ifne1 pigt rel
ctla4 rag2 adora2a faf1 il1rn piwil1 satb1
cul3 rela atrx fas irf2 pla2g6 serpinb4
cxcr4 rnase1 atxn3 faslg itgb3 pou4f1 siglec8
cyp2e1 sgpp1 bcl2l1 fcer2 klf2 ppp1r9b smpd1
cyp3a4 tfap4 bircabp foxo1 klra1 ppp2r1b spn
erbb3 thbs1 cast gal lrp5 prdm2 stk4
erg traf4 ccl27 gimap5 mdm4 ptgs2 syk
fyn zmym2 cd28 gng2 mll ptk2 thra
hla-g cdk6 gria2 mpo ptpn22 tnfsf15
ifih1 cyp2e1 grik2 nol3 ptprc traf5
ifna2 cyp3a4 grm1 nos1 ptprz1 trps1
igf1r dcc hint1 nrtn rbl2 znf10
PhagocytosisBMC Medical Genomics 2008, 1:33 http://www.biomedcentral.com/1755-8794/1/33
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duction). The short exposure time warranted a drug con-
centration higher than that generally used in animal
studies [19], however, some studies in cell culture systems
have employed rapamycin concentrations as high as 15–
20 μM before observing an impact on cell growth [20].
The selection was also dictated too by the fact that
rapamycins' effect on translation initiation has been
extensively studied. We have demonstrated that this
approach can be coupled to a high-throughput analysis of
the polysomal transcript populations.
Treatment with rapamycin limits the availability of eIF4E
via its sequestration into an inactive complex with the
hypophosphorylated 4E-BPs. Such a scenario represses
global translation rates but with an effect more marked on
those mRNAs containing structured 5' UTRs and those
containing TOP elements. Indeed, when TOP containing
transcripts were identified in our array they were always
down-regulated (Table 2). Additionally, although the
polysome profiles demonstrated an overall translational
repression, the position of the vast majority of mRNAs on
the gradient (i.e. the transcript populations in both the
heavy and light polysomes) was largely unperturbed by
the drug (i.e. there was little movement of transcripts from
heavy to light polysomes, a somewhat unanticipated
response), indicating that the affinity of re-recruitment of
ribosomes onto these mRNAs (as reflected by the number
of ribosomes per transcript) was largely unchanged.
A number of translational profiling studies examining the
effect of rapamycin in mammalian cells have already been
reported. In one of these, the effect of rapamycin on the
polysomal distribution of mRNAs was demonstrated to
be coupled to the activity of AKT [7], a result that demon-
strates the extent to which a drugs effect can be modulated
by the physiological status of the cell. This interpretation
has become even more convoluted following the observa-
tion that prolonged rapamycin treatment may inhibit AKT
signalling by interfering with the assembly of the second
mTOR complex, mTORC2 [21]. However, with regards to
the two transcripts characterised in this work as strongly
up-regulated, namely cyclin D1 and c-myc, the former was
down-regulated in our screen (×1.5 fold), and the latter
gave values that were not considered statistically signifi-
cant. Other studies have also failed to observe changes in
the polysomal occupancy of the cyclin D1 mRNA in the
presence of rapamycin [9,10,22]. These differences may
reflect the cell lines and/or the experimental procedures
employed. Both cyclin D1 and c-myc were proposed to
carry IRESes within the 5' UTR, and IRES activity has been
reported to show cell type specificity linked to the availa-
bility of ITAFs (IRES Trans-Acting Factors) [23]. Further-
more, the responsiveness of these IRESes to rapamycin
Upregulated Downregulated
cd36 klf2
fas mpo
fcgr2a pla2g6
hck syk
itgb3
The 1160 mRNAs identified in the microarray screen (as listed in Additional File 2) were plotted onto biological networks using the Ingenuity 
Pathway Analysis Software package. Those whose protein products are involved in inflammation, phagocytosis, cell growth/proliferation and cell 
death are listed.
Table 1: List of transcripts regulated by rapamycin (Ingenuity classification) (Continued)
Table 2: List of TOP mRNAs detected in the array.
LIGHT POLYSOME UP LIGHT POLYSOME DOWN HEAVY POLYSOME DOWN
(NONE) rpl5 (-1.5) rplP0 (-2.7)
rpl14 (-2.5) rpl36 (-1.5)
rpl21 (-5.1) eef2 (-1.5)
HEAVY POLYSOME UP rpl38 (-1.5) (translation elongation factor)
(NONE) rps11 (-2.1)
rps19 (-1.5)
rps21 (-2.1)
rps28 (-1.6)
eftuD1 (-5.5)
(translation elongation factor)BMC Medical Genomics 2008, 1:33 http://www.biomedcentral.com/1755-8794/1/33
Page 9 of 11
(page number not for citation purposes)
Real-Time RT-PCR analysis Figure 3
Real-Time RT-PCR analysis. (A). A schematic representation of the intensity values of transcripts selected for the RT-PCR 
validation. In the upper panel, the horizontal bars represented the value range for each mRNA on the array. The lower panel 
plots the distribution of regulated genes (×2.5 fold cut-off selection) relative to the probe set values. (B). RT-PCR values were 
normalised to those obtained from two housekeeping genes and the fold change indicates the difference in the DMSO and 
rapamycin values after normalisation. The DMSO value was arbitrarily set at 1. The results are compared with those obtained 
from the microarray. The variation in the total mRNA extracted is also represented. The 2.5 fold difference used for the 
screening is represented by the dotted lines (2.5 and 0.4). Each bar is representative of 2 independent RT-PCR assays per-
formed in triplicate. Bars indicate the SEM.
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was shown to be tightly coupled to the cellular activity of
the AKT and RAF/MEK/ERK signalling cascades, features
that may also show cell-type variation [24]. However, the
slight reduction that we observed in the polysomal levels
of the cyclin D1 mRNA would be consistent with other
reports indicating that its expression was sensitive to the
levels of eIF4E [25,26]. Finally, the earlier profiling study
followed changes in the steady-state polysomal popula-
tions after extended exposure to the drug, whilst in the
current work we have followed a competitive re-associa-
tion. These processes may have altered initiation factor
requirements, which could impact on the mRNA popula-
tions that respond. Indeed, it has been proposed that
eIF4GII but not eIF4GI is required for re-initiation subse-
quent to a hypertonic shock [27]. Nonetheless, a listing of
transcripts detected in both studies demonstrated that the
majority behaved similarly (see Additional File 3).
Conclusion
In summary, a major effort is underway to use high den-
sity microarray profiles to study how different drug
regimes impact on the polysomal mRNA populations.
These studies provide insights into how cellular gene
expression is regulated at the level of translation initia-
tion, the rate limiting step in protein expression. Changes
in this read-out are a very rapid cellular response to phys-
iological perturbations. The method that we have out-
lined permits a specific analysis of how a drug impacts on
transcript-ribosome association. This early response
almost certainly conditions subsequent cell behaviour
during extended exposure. The choice of rapamycin for
this "proof-of-principle" work was not arbitrary since the
impact of this drug on translation initiation has been
extensively studied. The technique offers the possibility of
establishing molecular fingerprints for different tumour
derived cell types and drug regimes [28]. In addition, it
provides a very powerful technique to analyse the early
events in translational control at the level of mRNA:ribos-
ome association.
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